NTLA Q1 2017 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+249.7% YoY

Gross Profit

-$7M-116.1% margin

Operating Income

-$13M-208.3% margin

Net Income

-$13M-203.2% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+10.4%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$16M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$279M

Total Liabilities

$79M

Stockholders' Equity

$200M

Cash & Equivalents

$258M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$2M	+249.7%
Gross Profit	-$7M	-$3M	-109.3%
Operating Income	-$13M	-$7M	-93.4%
Net Income	-$13M	-$7M	-88.8%